View ValuationMedCap 将来の成長Future 基準チェック /36MedCap利益と収益がそれぞれ年間14.9%と6.6%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に16.1% 14.8%なると予測されています。主要情報14.9%収益成長率14.77%EPS成長率Life Sciences 収益成長19.2%収益成長率6.6%将来の株主資本利益率16.10%アナリストカバレッジLow最終更新日29 Apr 2026今後の成長に関する最新情報Price Target Changed • Apr 29Price target increased by 9.1% to kr575Up from kr527, the current price target is an average from 2 analysts. New target price is 20% above last closing price of kr478. Stock is up 9.9% over the past year. The company is forecast to post earnings per share of kr19.24 for next year compared to kr14.67 last year.すべての更新を表示Recent updatesBuy Or Sell Opportunity • Jun 03Now 20% undervaluedOver the last 90 days, the stock has risen 2.4% to kr502. The fair value is estimated to be kr628, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 14%. Revenue is forecast to grow by 15% in 2 years. Earnings are forecast to grow by 41% in the next 2 years.Valuation Update With 7 Day Price Move • May 11Investor sentiment improves as stock rises 16%After last week's 16% share price gain to kr529, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 28x in the Life Sciences industry in Sweden. Total returns to shareholders of 78% over the past three years.Reported Earnings • May 05First quarter 2026 earnings released: EPS: kr3.72 (vs kr3.37 in 1Q 2025)First quarter 2026 results: EPS: kr3.72 (up from kr3.37 in 1Q 2025). Revenue: kr564.5m (up 14% from 1Q 2025). Net income: kr55.9m (up 11% from 1Q 2025). Profit margin: 9.9% (in line with 1Q 2025). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 17% per year.Buy Or Sell Opportunity • May 04Now 23% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.6% to kr458. The fair value is estimated to be kr598, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 15%.Price Target Changed • Apr 29Price target increased by 9.1% to kr575Up from kr527, the current price target is an average from 2 analysts. New target price is 20% above last closing price of kr478. Stock is up 9.9% over the past year. The company is forecast to post earnings per share of kr19.24 for next year compared to kr14.67 last year.New Risk • Apr 10New major risk - Revenue sizeThe company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risk Large one-off items impacting financial results.お知らせ • Mar 31MedCap AB (publ), Annual General Meeting, May 04, 2026MedCap AB (publ), Annual General Meeting, May 04, 2026, at 16:00 W. Europe Standard Time. Location: at iva, grev turegatan 16 in stockholm, stockholm SwedenRecent Insider Transactions • Feb 13Head of Business Area Specialty Pharma recently bought kr780k worth of stockOn the 9th of February, Anders Larnholt bought around 2k shares on-market at roughly kr520 per share. This transaction amounted to 60% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold kr25m more in shares than they bought in the last 12 months.Reported Earnings • Feb 10Full year 2025 earnings released: EPS: kr14.67 (vs kr14.00 in FY 2024)Full year 2025 results: EPS: kr14.67 (up from kr14.00 in FY 2024). Revenue: kr2.13b (up 18% from FY 2024). Net income: kr219.8m (up 6.0% from FY 2024). Profit margin: 10% (down from 12% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Feb 06MedCap AB (publ) to Report Fiscal Year 2026 Results on Feb 05, 2027MedCap AB (publ) announced that they will report fiscal year 2026 results on Feb 05, 2027Board Change • Feb 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. Independent Director Otto Ankarcrona was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.分析記事 • Jan 30Estimating The Fair Value Of MedCap AB (publ) (STO:MCAP)Key Insights Using the 2 Stage Free Cash Flow to Equity, MedCap fair value estimate is kr577 Current share price of...Recent Insider Transactions • Dec 08Chairman recently sold kr3.4m worth of stockOn the 5th of December, Karl Tobieson sold around 6k shares on-market at roughly kr537 per share. This transaction amounted to 4.6% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Karl has been a net seller over the last 12 months, reducing personal holdings by kr26m.分析記事 • Nov 06Earnings Troubles May Signal Larger Issues for MedCap (STO:MCAP) ShareholdersMedCap AB (publ)'s ( STO:MCAP ) stock showed strength, with investors undeterred by its weak earnings report...Reported Earnings • Oct 26Third quarter 2025 earnings released: EPS: kr3.42 (vs kr3.57 in 3Q 2024)Third quarter 2025 results: EPS: kr3.42 (down from kr3.57 in 3Q 2024). Revenue: kr504.8m (up 22% from 3Q 2024). Net income: kr51.2m (down 3.2% from 3Q 2024). Profit margin: 10% (down from 13% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Oct 25MedCap AB (publ) to Report Q3, 2026 Results on Oct 23, 2026MedCap AB (publ) announced that they will report Q3, 2026 results on Oct 23, 2026分析記事 • Sep 25Is MedCap (STO:MCAP) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Aug 28A Look At The Intrinsic Value Of MedCap AB (publ) (STO:MCAP)Key Insights The projected fair value for MedCap is kr683 based on 2 Stage Free Cash Flow to Equity MedCap's kr621...Reported Earnings • Jul 24Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: kr524.1m (up 14% from 2Q 2024). Net income: kr53.7m (down 5.5% from 2Q 2024). Profit margin: 10% (down from 12% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jul 24+ 2 more updatesMedCap AB (publ) to Report Q1, 2026 Results on Apr 29, 2026MedCap AB (publ) announced that they will report Q1, 2026 results on Apr 29, 2026Valuation Update With 7 Day Price Move • Jul 23Investor sentiment improves as stock rises 16%After last week's 16% share price gain to kr616, the stock trades at a trailing P/E ratio of 45.9x. Average forward P/E is 24x in the Life Sciences industry in Sweden. Total returns to shareholders of 199% over the past three years.分析記事 • Jul 13MedCap AB (publ)'s (STO:MCAP) Shares Climb 27% But Its Business Is Yet to Catch UpMedCap AB (publ) ( STO:MCAP ) shares have continued their recent momentum with a 27% gain in the last month alone. The...お知らせ • Jun 25MedCap AB (publ) (OM:MCAP) acquired XGX PharmaMedCap AB (publ) (OM:MCAP) agreed to acquire XGX Pharma on June 25, 2025. MedCap AB (publ) (OM:MCAP) completed acquisition of XGX Pharma on June 25, 2025.Recent Insider Transactions • May 15Chairman recently sold kr22m worth of stockOn the 12th of May, Karl Tobieson sold around 50k shares on-market at roughly kr444 per share. This transaction amounted to 28% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Karl's only on-market trade for the last 12 months.お知らせ • May 10MedCap AB (publ) (OM:MCAP) announces an Equity Buyback for SEK 26 million worth of its shares.MedCap AB (publ) (OM:MCAP) announces a share repurchase program. Under the program, the company will repurchase up to SEK 26 million worth of its shares. The shares shall be acquired at a price per share within the price range applicable on Nasdaq Stockholm at any time, which refers to the interval between the highest bid price and the lowest ask price published continuously by Nasdaq Stockholm. The purpose of the program is to secure the Company's commitment to share-based incentive programs (LTIP 2025/2028) through holdings of unvested shares and to continuously adapt the Company's capital structure to the Company's capital needs and thereby contribute to increased shareholder value, and to enable future acquisitions of companies or businesses to be made through payment with own shares. The program will be valid till August 29, 2025. As of May 7, 2025, the company had 14,981,353 outstanding shares and 0 treasury shares.分析記事 • May 07MedCap (STO:MCAP) Strong Profits May Be Masking Some Underlying IssuesMedCap AB (publ) ( STO:MCAP ) just released a solid earnings report, and the stock displayed some strength. Despite...分析記事 • May 04Subdued Growth No Barrier To MedCap AB (publ) (STO:MCAP) With Shares Advancing 28%MedCap AB (publ) ( STO:MCAP ) shareholders would be excited to see that the share price has had a great month, posting...Reported Earnings • Apr 30First quarter 2025 earnings released: EPS: kr3.37 (vs kr3.78 in 1Q 2024)First quarter 2025 results: EPS: kr3.37 (down from kr3.78 in 1Q 2024). Revenue: kr498.3m (up 7.9% from 1Q 2024). Net income: kr50.5m (down 9.8% from 1Q 2024). Profit margin: 10% (down from 12% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Apr 29Why We Think The CEO Of MedCap AB (publ) (STO:MCAP) May Soon See A Pay RiseKey Insights MedCap to hold its Annual General Meeting on 5th of May Total pay for CEO Anders Dahlberg includes kr3.03m...Buy Or Sell Opportunity • Apr 19Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.2% to kr386. The fair value is estimated to be kr482, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 30%.お知らせ • Apr 03MedCap AB (publ), Annual General Meeting, May 05, 2025MedCap AB (publ), Annual General Meeting, May 05, 2025, at 16:00 W. Europe Standard Time. Location: iva, grev turegatan 16, stockholm SwedenBuy Or Sell Opportunity • Feb 19Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 27% to kr395. The fair value is estimated to be kr499, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 30%.Recent Insider Transactions • Feb 14Chief Executive Officer recently bought kr3.9m worth of stockOn the 12th of February, Anders Dahlberg bought around 10k shares on-market at roughly kr391 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Anders has been a buyer over the last 12 months, purchasing a net total of kr4.2m worth in shares.分析記事 • Feb 03Some MedCap AB (publ) (STO:MCAP) Shareholders Look For Exit As Shares Take 34% PoundingMedCap AB (publ) ( STO:MCAP ) shareholders that were waiting for something to happen have been dealt a blow with a 34...お知らせ • Feb 02MedCap AB (publ) to Report Q3, 2025 Results on Oct 24, 2025MedCap AB (publ) announced that they will report Q3, 2025 results on Oct 24, 2025Reported Earnings • Feb 01Full year 2024 earnings: EPS in line with expectations, revenues disappointFull year 2024 results: EPS: kr14.00 (up from kr11.63 in FY 2023). Revenue: kr1.84b (up 15% from FY 2023). Net income: kr207.4m (up 20% from FY 2023). Profit margin: 11% (in line with FY 2023). Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Jan 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 5.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Buy Or Sell Opportunity • Jan 17Now 33% undervalued after recent price dropOver the last 90 days, the stock has fallen 24% to kr411. The fair value is estimated to be kr609, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 34%. Revenue is forecast to grow by 23% in 2 years. Earnings are forecast to grow by 22% in the next 2 years.Buy Or Sell Opportunity • Jan 02Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 27% to kr615. The fair value is estimated to be kr501, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 34%.Buy Or Sell Opportunity • Dec 16Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 22% to kr601. The fair value is estimated to be kr500, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 34%.Recent Insider Transactions Derivative • Dec 09Chief Executive Officer exercised options and sold kr11m worth of stockOn the 4th of December, Anders Dahlberg exercised 45.00k options at around kr217, then sold 35k of the shares acquired at an average of kr544 per share and kept the remainder. For the year to December 2021, Anders' total compensation was 45% salary and 55% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since December 2023, Anders' direct individual holding has increased from 19.46k shares to 20.00k. Company insiders have collectively sold kr19m more than they bought, via options and on-market transactions in the last 12 months.分析記事 • Nov 16We Think MedCap (STO:MCAP) Can Manage Its Debt With EaseLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: kr3.57 (vs kr2.59 in 3Q 2023)Third quarter 2024 results: EPS: kr3.57 (up from kr2.59 in 3Q 2023). Revenue: kr426.0m (up 17% from 3Q 2023). Net income: kr52.9m (up 38% from 3Q 2023). Profit margin: 12% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year whereas the company’s share price has increased by 39% per year.分析記事 • Oct 18MedCap AB (publ)'s (STO:MCAP) Earnings Haven't Escaped The Attention Of InvestorsWith a price-to-earnings (or "P/E") ratio of 36x MedCap AB (publ) ( STO:MCAP ) may be sending very bearish signals at...Recent Insider Transactions • Sep 23Chief Executive Officer recently bought kr265k worth of stockOn the 20th of September, Anders Dahlberg bought around 541 shares on-market at roughly kr491 per share. This transaction amounted to 2.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Anders' only on-market trade for the last 12 months.Reported Earnings • Jul 25Second quarter 2024 earnings released: EPS: kr3.84 (vs kr3.16 in 2Q 2023)Second quarter 2024 results: EPS: kr3.84 (up from kr3.16 in 2Q 2023). Revenue: kr469.9m (up 22% from 2Q 2023). Net income: kr56.8m (up 21% from 2Q 2023). Profit margin: 12% (in line with 2Q 2023). Over the last 3 years on average, earnings per share has increased by 35% per year whereas the company’s share price has increased by 38% per year.お知らせ • Jul 25MedCap AB (publ) to Report Q2, 2025 Results on Jul 23, 2025MedCap AB (publ) announced that they will report Q2, 2025 results on Jul 23, 2025Buy Or Sell Opportunity • Jul 01Now 17% undervaluedOver the last 90 days, the stock has risen 40% to kr523. The fair value is estimated to be kr631, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 34%.Buy Or Sell Opportunity • Jun 25Now 21% undervaluedOver the last 90 days, the stock has risen 32% to kr500. The fair value is estimated to be kr629, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 34%.分析記事 • Jun 06Estimating The Intrinsic Value Of MedCap AB (publ) (STO:MCAP)Key Insights The projected fair value for MedCap is kr631 based on 2 Stage Free Cash Flow to Equity Current share price...分析記事 • May 21MedCap AB (publ) (STO:MCAP) Stocks Shoot Up 33% But Its P/E Still Looks ReasonableThe MedCap AB (publ) ( STO:MCAP ) share price has done very well over the last month, posting an excellent gain of 33...Buy Or Sell Opportunity • May 13Now 21% undervaluedOver the last 90 days, the stock has risen 26% to kr494. The fair value is estimated to be kr626, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 34%.お知らせ • May 12MedCap AB (publ) to Report Q1, 2025 Results on Apr 29, 2025MedCap AB (publ) announced that they will report Q1, 2025 results on Apr 29, 2025分析記事 • May 04Should You Be Adding MedCap (STO:MCAP) To Your Watchlist Today?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Reported Earnings • May 04First quarter 2024 earnings released: EPS: kr3.78 (vs kr1.68 in 1Q 2023)First quarter 2024 results: EPS: kr3.78 (up from kr1.68 in 1Q 2023). Revenue: kr463.1m (up 22% from 1Q 2023). Net income: kr56.0m (up 126% from 1Q 2023). Profit margin: 12% (up from 6.5% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth.お知らせ • Apr 03MedCap AB (publ), Annual General Meeting, May 06, 2024MedCap AB (publ), Annual General Meeting, May 06, 2024.お知らせ • Mar 29MedCap AB (publ) to Report Fiscal Year 2024 Results on Jan 31, 2025MedCap AB (publ) announced that they will report fiscal year 2024 results on Jan 31, 2025分析記事 • Feb 15MedCap AB (publ)'s (STO:MCAP) P/E Is Still On The Mark Following 25% Share Price BounceDespite an already strong run, MedCap AB (publ) ( STO:MCAP ) shares have been powering on, with a gain of 25% in the...Reported Earnings • Feb 02Full year 2023 earnings released: EPS: kr11.63 (vs kr7.94 in FY 2022)Full year 2023 results: EPS: kr11.63 (up from kr7.94 in FY 2022). Revenue: kr1.60b (up 43% from FY 2022). Net income: kr172.2m (up 46% from FY 2022). Profit margin: 11% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Feb 01Investor sentiment improves as stock rises 19%After last week's 19% share price gain to kr380, the stock trades at a trailing P/E ratio of 37.4x. Average trailing P/E is 49x in the Life Sciences industry in Sweden. Total returns to shareholders of 88% over the past three years.分析記事 • Dec 21Is Now The Time To Put MedCap (STO:MCAP) On Your Watchlist?The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...お知らせ • Oct 29MedCap AB (publ) to Report Q3, 2024 Results on Oct 25, 2024MedCap AB (publ) announced that they will report Q3, 2024 results on Oct 25, 2024Reported Earnings • Oct 29Third quarter 2023 earnings released: EPS: kr2.59 (vs kr2.47 in 3Q 2022)Third quarter 2023 results: EPS: kr2.59 (up from kr2.47 in 3Q 2022). Revenue: kr368.2m (up 52% from 3Q 2022). Net income: kr38.3m (up 4.6% from 3Q 2022). Profit margin: 10% (down from 15% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 31MedCap AB (publ) to Report First Half, 2024 Results on Jul 19, 2024MedCap AB (publ) announced that they will report first half, 2024 results on Jul 19, 2024Reported Earnings • Jul 29Second quarter 2023 earnings released: EPS: kr3.16 (vs kr1.42 in 2Q 2022)Second quarter 2023 results: EPS: kr3.16 (up from kr1.42 in 2Q 2022). Revenue: kr390.0m (up 37% from 2Q 2022). Net income: kr46.8m (up 123% from 2Q 2022). Profit margin: 12% (up from 7.4% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 32% per year whereas the company’s share price has increased by 27% per year.お知らせ • Jul 25MedCap AB (publ) (OM:MCAP) signed an agreement to acquire SurgiCube International B.V. for €8 million.MedCap AB (publ) (OM:MCAP) signed an agreement to acquire Surgicube International B.V. for €8 million on July 24, 2023. Under the transaction, MedCap pays €6 million and adjustments for net debt / cash at closing and an earn-out up to €2 million based on the gross profit growth until December 2024. SurgiCube’s sales in the last 12 months amounted to approximately €3.7 million with almost 24% EBITDA-margin. Key individuals in the business have committed to remain as minority owners, and the former majority owner Ger Vijfvinkel has committed to remain as managing director and then as advisor during a transition phase.分析記事 • May 06Do MedCap's (STO:MCAP) Earnings Warrant Your Attention?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...お知らせ • May 05MedCap AB (publ) to Report Q1, 2024 Results on May 03, 2024MedCap AB (publ) announced that they will report Q1, 2024 results on May 03, 2024Reported Earnings • May 03First quarter 2023 earnings released: EPS: kr1.68 (vs kr1.32 in 1Q 2022)First quarter 2023 results: EPS: kr1.68 (up from kr1.32 in 1Q 2022). Revenue: kr384.0m (up 46% from 1Q 2022). Net income: kr24.8m (up 27% from 1Q 2022). Profit margin: 6.5% (down from 7.5% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.Reported Earnings • Feb 12Full year 2022 earnings released: EPS: kr7.94 (vs kr6.52 in FY 2021)Full year 2022 results: EPS: kr7.94 (up from kr6.52 in FY 2021). Revenue: kr1.15b (up 24% from FY 2021). Net income: kr117.6m (up 22% from FY 2021). Profit margin: 10% (in line with FY 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.分析記事 • Nov 23These 4 Measures Indicate That MedCap (STO:MCAP) Is Using Debt SafelyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Board Change • Nov 16High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. 1 highly experienced director. Independent Director Anders Hansen is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 30Third quarter 2022 earnings released: EPS: kr2.47 (vs kr1.73 in 3Q 2021)Third quarter 2022 results: EPS: kr2.47 (up from kr1.73 in 3Q 2021). Revenue: kr264.0m (up 31% from 3Q 2021). Net income: kr36.6m (up 43% from 3Q 2021). Profit margin: 14% (up from 13% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.分析記事 • Sep 21We Ran A Stock Scan For Earnings Growth And MedCap (STO:MCAP) Passed With EaseFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Buying Opportunity • Sep 13Now 21% undervaluedOver the last 90 days, the stock is up 17%. The fair value is estimated to be kr267, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 28%.Buying Opportunity • Aug 02Now 21% undervaluedOver the last 90 days, the stock is up 36%. The fair value is estimated to be kr273, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 28%.お知らせ • Jul 31MedCap AB (publ) to Report Q2, 2023 Results on Jul 28, 2023MedCap AB (publ) announced that they will report Q2, 2023 results on Jul 28, 2023Board Change • Jul 30High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. 1 highly experienced director. Independent Director Anders Hansen is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Board Change • Jun 02High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. 1 highly experienced director. Independent Director Anders Hansen is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 12+ 1 more updateMedCap AB (publ) to Report Q1, 2023 Results on May 03, 2023MedCap AB (publ) announced that they will report Q1, 2023 results on May 03, 2023Reported Earnings • May 06First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2022 results: EPS: kr1.32 (up from kr0.99 in 1Q 2021). Revenue: kr265.8m (up 19% from 1Q 2021). Net income: kr19.6m (up 34% from 1Q 2021). Profit margin: 7.4% (up from 6.6% in 1Q 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 4.3%. Earnings per share (EPS) exceeded analyst estimates by 13%. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.分析記事 • Apr 29Does MedCap (STO:MCAP) Deserve A Spot On Your Watchlist?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...お知らせ • Mar 29MedCap AB (publ) to Report Q4, 2022 Results on Feb 10, 2023MedCap AB (publ) announced that they will report Q4, 2022 results on Feb 10, 2023Reported Earnings • Feb 11Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: EPS: kr6.52 (up from kr4.36 in FY 2020). Revenue: kr939.6m (up 15% from FY 2020). Net income: kr96.5m (up 54% from FY 2020). Profit margin: 10% (up from 7.6% in FY 2020). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 4.3%. Earnings per share (EPS) exceeded analyst estimates by 13%. Over the last 3 years on average, earnings per share has increased by 29% per year and the company’s share price has also increased by 29% per year.分析記事 • Feb 01MedCap (STO:MCAP) Seems To Use Debt Rather SparinglyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Valuation Update With 7 Day Price Move • Jan 31Investor sentiment improved over the past weekAfter last week's 18% share price gain to kr162, the stock trades at a trailing P/E ratio of 31.3x. Average trailing P/E is 51x in the Life Sciences industry in Sweden. Total returns to shareholders of 94% over the past three years.Buying Opportunity • Jan 21Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 24%. The fair value is estimated to be kr184, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.4% per annum over the last 3 years. Earnings per share has grown by 32% per annum over the last 3 years.Board Change • Jan 02High number of new directorsChairman Karl Tobieson was the last director to join the board, commencing their role in 2021.Recent Insider Transactions • Dec 30Chief Executive Officer recently bought kr348k worth of stockOn the 27th of December, Anders Dahlberg bought around 2k shares on-market at roughly kr174 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr828k. Anders has been a buyer over the last 12 months, purchasing a net total of kr1.1m worth in shares.Recent Insider Transactions • Dec 15Investment Manager recently bought kr828k worth of stockOn the 13th of December, Lars Ångman bought around 5k shares on-market at roughly kr166 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr1.9m more in shares than they have sold in the last 12 months.Reported Earnings • Oct 30Third quarter 2021 earnings released: EPS kr1.73 (vs kr0.89 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr216.0m (up 23% from 3Q 2020). Net income: kr25.6m (up 95% from 3Q 2020). Profit margin: 12% (up from 7.5% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 32% per year whereas the company’s share price has increased by 34% per year.分析記事 • Aug 03Should You Be Adding MedCap (STO:MCAP) To Your Watchlist Today?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...Reported Earnings • Jul 31Second quarter 2021 earnings released: EPS kr1.06 (vs kr1.33 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: kr237.1m (up 13% from 2Q 2020). Net income: kr15.7m (down 18% from 2Q 2020). Profit margin: 6.6% (down from 9.1% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.分析記事 • May 27Does MedCap (STO:MCAP) Have A Healthy Balance Sheet?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Valuation Update With 7 Day Price Move • May 12Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to kr206, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 40x in the Life Sciences industry in Europe. Total returns to shareholders of 170% over the past three years.Recent Insider Transactions • May 09Independent Chairman of the Board recently bought kr1.1m worth of stockOn the 7th of May, Peter von Ehrenheim bought around 5k shares on-market at roughly kr220 per share. This was the largest purchase by an insider in the last 3 months. This was Peter's only on-market trade for the last 12 months.業績と収益の成長予測OM:MCAP - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20282,615343364441112/31/20272,463308335409112/31/20262,30826629036213/31/20262,176225275339N/A12/31/20252,110220281343N/A9/30/20251,996197258318N/A6/30/20251,908199267326N/A3/31/20251,844202261323N/A12/31/20241,807207294360N/A9/30/20241,791228251308N/A6/30/20241,742214244299N/A3/31/20241,671203219268N/A12/31/20231,589172189228N/A9/30/20231,46615077114N/A6/30/20231,3431496197N/A3/31/20231,2411234782N/A12/31/20221,1241184186N/A9/30/20221,056118100167N/A6/30/20221,01710778146N/A3/31/202296710285156N/A12/31/20219269755116N/A9/30/20218967677109N/A6/30/2021869646090N/A3/31/20218456779104N/A12/31/20208286391115N/A9/30/2020802556488N/A6/30/20207865375101N/A3/31/2020763473862N/A12/31/201975755N/A71N/A9/30/201973443N/A87N/A6/30/201974041N/A107N/A3/31/201972732N/A103N/A12/31/201870924N/A91N/A9/30/201871614N/A57N/A6/30/20186898N/A27N/A3/31/201866010N/A46N/A12/31/20176177N/A41N/A10/31/201777911N/A79N/A7/31/20178023N/A85N/A4/30/20178530N/A81N/A1/31/20179015N/A32N/A10/31/201689710N/A-18N/A7/31/201687419N/A-44N/A4/30/201681820N/A-15N/A1/31/201681718N/A-60N/A10/31/201581817N/A-28N/A7/31/20158258N/A14N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: MCAPの予測収益成長率 (年間14.9% ) は 貯蓄率 ( 2% ) を上回っています。収益対市場: MCAPの収益 ( 14.9% ) はSwedish市場 ( 8.6% ) よりも速いペースで成長すると予測されています。高成長収益: MCAPの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: MCAPの収益 ( 6.6% ) Swedish市場 ( 0.02% ) よりも速いペースで成長すると予測されています。高い収益成長: MCAPの収益 ( 6.6% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: MCAPの 自己資本利益率 は、3年後には低くなると予測されています ( 16.1 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/16 01:36終値2026/06/16 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MedCap AB (publ) 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関null nullABG Sundal CollierBjorn RydellABG Sundal Collier SponsoredHans MählerNordea Markets2 その他のアナリストを表示
Price Target Changed • Apr 29Price target increased by 9.1% to kr575Up from kr527, the current price target is an average from 2 analysts. New target price is 20% above last closing price of kr478. Stock is up 9.9% over the past year. The company is forecast to post earnings per share of kr19.24 for next year compared to kr14.67 last year.
Buy Or Sell Opportunity • Jun 03Now 20% undervaluedOver the last 90 days, the stock has risen 2.4% to kr502. The fair value is estimated to be kr628, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 14%. Revenue is forecast to grow by 15% in 2 years. Earnings are forecast to grow by 41% in the next 2 years.
Valuation Update With 7 Day Price Move • May 11Investor sentiment improves as stock rises 16%After last week's 16% share price gain to kr529, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 28x in the Life Sciences industry in Sweden. Total returns to shareholders of 78% over the past three years.
Reported Earnings • May 05First quarter 2026 earnings released: EPS: kr3.72 (vs kr3.37 in 1Q 2025)First quarter 2026 results: EPS: kr3.72 (up from kr3.37 in 1Q 2025). Revenue: kr564.5m (up 14% from 1Q 2025). Net income: kr55.9m (up 11% from 1Q 2025). Profit margin: 9.9% (in line with 1Q 2025). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 17% per year.
Buy Or Sell Opportunity • May 04Now 23% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.6% to kr458. The fair value is estimated to be kr598, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 15%.
Price Target Changed • Apr 29Price target increased by 9.1% to kr575Up from kr527, the current price target is an average from 2 analysts. New target price is 20% above last closing price of kr478. Stock is up 9.9% over the past year. The company is forecast to post earnings per share of kr19.24 for next year compared to kr14.67 last year.
New Risk • Apr 10New major risk - Revenue sizeThe company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risk Large one-off items impacting financial results.
お知らせ • Mar 31MedCap AB (publ), Annual General Meeting, May 04, 2026MedCap AB (publ), Annual General Meeting, May 04, 2026, at 16:00 W. Europe Standard Time. Location: at iva, grev turegatan 16 in stockholm, stockholm Sweden
Recent Insider Transactions • Feb 13Head of Business Area Specialty Pharma recently bought kr780k worth of stockOn the 9th of February, Anders Larnholt bought around 2k shares on-market at roughly kr520 per share. This transaction amounted to 60% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold kr25m more in shares than they bought in the last 12 months.
Reported Earnings • Feb 10Full year 2025 earnings released: EPS: kr14.67 (vs kr14.00 in FY 2024)Full year 2025 results: EPS: kr14.67 (up from kr14.00 in FY 2024). Revenue: kr2.13b (up 18% from FY 2024). Net income: kr219.8m (up 6.0% from FY 2024). Profit margin: 10% (down from 12% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Feb 06MedCap AB (publ) to Report Fiscal Year 2026 Results on Feb 05, 2027MedCap AB (publ) announced that they will report fiscal year 2026 results on Feb 05, 2027
Board Change • Feb 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. Independent Director Otto Ankarcrona was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Jan 30Estimating The Fair Value Of MedCap AB (publ) (STO:MCAP)Key Insights Using the 2 Stage Free Cash Flow to Equity, MedCap fair value estimate is kr577 Current share price of...
Recent Insider Transactions • Dec 08Chairman recently sold kr3.4m worth of stockOn the 5th of December, Karl Tobieson sold around 6k shares on-market at roughly kr537 per share. This transaction amounted to 4.6% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Karl has been a net seller over the last 12 months, reducing personal holdings by kr26m.
分析記事 • Nov 06Earnings Troubles May Signal Larger Issues for MedCap (STO:MCAP) ShareholdersMedCap AB (publ)'s ( STO:MCAP ) stock showed strength, with investors undeterred by its weak earnings report...
Reported Earnings • Oct 26Third quarter 2025 earnings released: EPS: kr3.42 (vs kr3.57 in 3Q 2024)Third quarter 2025 results: EPS: kr3.42 (down from kr3.57 in 3Q 2024). Revenue: kr504.8m (up 22% from 3Q 2024). Net income: kr51.2m (down 3.2% from 3Q 2024). Profit margin: 10% (down from 13% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Oct 25MedCap AB (publ) to Report Q3, 2026 Results on Oct 23, 2026MedCap AB (publ) announced that they will report Q3, 2026 results on Oct 23, 2026
分析記事 • Sep 25Is MedCap (STO:MCAP) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • Aug 28A Look At The Intrinsic Value Of MedCap AB (publ) (STO:MCAP)Key Insights The projected fair value for MedCap is kr683 based on 2 Stage Free Cash Flow to Equity MedCap's kr621...
Reported Earnings • Jul 24Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: kr524.1m (up 14% from 2Q 2024). Net income: kr53.7m (down 5.5% from 2Q 2024). Profit margin: 10% (down from 12% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jul 24+ 2 more updatesMedCap AB (publ) to Report Q1, 2026 Results on Apr 29, 2026MedCap AB (publ) announced that they will report Q1, 2026 results on Apr 29, 2026
Valuation Update With 7 Day Price Move • Jul 23Investor sentiment improves as stock rises 16%After last week's 16% share price gain to kr616, the stock trades at a trailing P/E ratio of 45.9x. Average forward P/E is 24x in the Life Sciences industry in Sweden. Total returns to shareholders of 199% over the past three years.
分析記事 • Jul 13MedCap AB (publ)'s (STO:MCAP) Shares Climb 27% But Its Business Is Yet to Catch UpMedCap AB (publ) ( STO:MCAP ) shares have continued their recent momentum with a 27% gain in the last month alone. The...
お知らせ • Jun 25MedCap AB (publ) (OM:MCAP) acquired XGX PharmaMedCap AB (publ) (OM:MCAP) agreed to acquire XGX Pharma on June 25, 2025. MedCap AB (publ) (OM:MCAP) completed acquisition of XGX Pharma on June 25, 2025.
Recent Insider Transactions • May 15Chairman recently sold kr22m worth of stockOn the 12th of May, Karl Tobieson sold around 50k shares on-market at roughly kr444 per share. This transaction amounted to 28% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Karl's only on-market trade for the last 12 months.
お知らせ • May 10MedCap AB (publ) (OM:MCAP) announces an Equity Buyback for SEK 26 million worth of its shares.MedCap AB (publ) (OM:MCAP) announces a share repurchase program. Under the program, the company will repurchase up to SEK 26 million worth of its shares. The shares shall be acquired at a price per share within the price range applicable on Nasdaq Stockholm at any time, which refers to the interval between the highest bid price and the lowest ask price published continuously by Nasdaq Stockholm. The purpose of the program is to secure the Company's commitment to share-based incentive programs (LTIP 2025/2028) through holdings of unvested shares and to continuously adapt the Company's capital structure to the Company's capital needs and thereby contribute to increased shareholder value, and to enable future acquisitions of companies or businesses to be made through payment with own shares. The program will be valid till August 29, 2025. As of May 7, 2025, the company had 14,981,353 outstanding shares and 0 treasury shares.
分析記事 • May 07MedCap (STO:MCAP) Strong Profits May Be Masking Some Underlying IssuesMedCap AB (publ) ( STO:MCAP ) just released a solid earnings report, and the stock displayed some strength. Despite...
分析記事 • May 04Subdued Growth No Barrier To MedCap AB (publ) (STO:MCAP) With Shares Advancing 28%MedCap AB (publ) ( STO:MCAP ) shareholders would be excited to see that the share price has had a great month, posting...
Reported Earnings • Apr 30First quarter 2025 earnings released: EPS: kr3.37 (vs kr3.78 in 1Q 2024)First quarter 2025 results: EPS: kr3.37 (down from kr3.78 in 1Q 2024). Revenue: kr498.3m (up 7.9% from 1Q 2024). Net income: kr50.5m (down 9.8% from 1Q 2024). Profit margin: 10% (down from 12% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Apr 29Why We Think The CEO Of MedCap AB (publ) (STO:MCAP) May Soon See A Pay RiseKey Insights MedCap to hold its Annual General Meeting on 5th of May Total pay for CEO Anders Dahlberg includes kr3.03m...
Buy Or Sell Opportunity • Apr 19Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.2% to kr386. The fair value is estimated to be kr482, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 30%.
お知らせ • Apr 03MedCap AB (publ), Annual General Meeting, May 05, 2025MedCap AB (publ), Annual General Meeting, May 05, 2025, at 16:00 W. Europe Standard Time. Location: iva, grev turegatan 16, stockholm Sweden
Buy Or Sell Opportunity • Feb 19Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 27% to kr395. The fair value is estimated to be kr499, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 30%.
Recent Insider Transactions • Feb 14Chief Executive Officer recently bought kr3.9m worth of stockOn the 12th of February, Anders Dahlberg bought around 10k shares on-market at roughly kr391 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Anders has been a buyer over the last 12 months, purchasing a net total of kr4.2m worth in shares.
分析記事 • Feb 03Some MedCap AB (publ) (STO:MCAP) Shareholders Look For Exit As Shares Take 34% PoundingMedCap AB (publ) ( STO:MCAP ) shareholders that were waiting for something to happen have been dealt a blow with a 34...
お知らせ • Feb 02MedCap AB (publ) to Report Q3, 2025 Results on Oct 24, 2025MedCap AB (publ) announced that they will report Q3, 2025 results on Oct 24, 2025
Reported Earnings • Feb 01Full year 2024 earnings: EPS in line with expectations, revenues disappointFull year 2024 results: EPS: kr14.00 (up from kr11.63 in FY 2023). Revenue: kr1.84b (up 15% from FY 2023). Net income: kr207.4m (up 20% from FY 2023). Profit margin: 11% (in line with FY 2023). Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Life Sciences industry in Sweden. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Jan 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 5.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Buy Or Sell Opportunity • Jan 17Now 33% undervalued after recent price dropOver the last 90 days, the stock has fallen 24% to kr411. The fair value is estimated to be kr609, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 34%. Revenue is forecast to grow by 23% in 2 years. Earnings are forecast to grow by 22% in the next 2 years.
Buy Or Sell Opportunity • Jan 02Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 27% to kr615. The fair value is estimated to be kr501, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 34%.
Buy Or Sell Opportunity • Dec 16Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 22% to kr601. The fair value is estimated to be kr500, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 34%.
Recent Insider Transactions Derivative • Dec 09Chief Executive Officer exercised options and sold kr11m worth of stockOn the 4th of December, Anders Dahlberg exercised 45.00k options at around kr217, then sold 35k of the shares acquired at an average of kr544 per share and kept the remainder. For the year to December 2021, Anders' total compensation was 45% salary and 55% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since December 2023, Anders' direct individual holding has increased from 19.46k shares to 20.00k. Company insiders have collectively sold kr19m more than they bought, via options and on-market transactions in the last 12 months.
分析記事 • Nov 16We Think MedCap (STO:MCAP) Can Manage Its Debt With EaseLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: kr3.57 (vs kr2.59 in 3Q 2023)Third quarter 2024 results: EPS: kr3.57 (up from kr2.59 in 3Q 2023). Revenue: kr426.0m (up 17% from 3Q 2023). Net income: kr52.9m (up 38% from 3Q 2023). Profit margin: 12% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year whereas the company’s share price has increased by 39% per year.
分析記事 • Oct 18MedCap AB (publ)'s (STO:MCAP) Earnings Haven't Escaped The Attention Of InvestorsWith a price-to-earnings (or "P/E") ratio of 36x MedCap AB (publ) ( STO:MCAP ) may be sending very bearish signals at...
Recent Insider Transactions • Sep 23Chief Executive Officer recently bought kr265k worth of stockOn the 20th of September, Anders Dahlberg bought around 541 shares on-market at roughly kr491 per share. This transaction amounted to 2.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Anders' only on-market trade for the last 12 months.
Reported Earnings • Jul 25Second quarter 2024 earnings released: EPS: kr3.84 (vs kr3.16 in 2Q 2023)Second quarter 2024 results: EPS: kr3.84 (up from kr3.16 in 2Q 2023). Revenue: kr469.9m (up 22% from 2Q 2023). Net income: kr56.8m (up 21% from 2Q 2023). Profit margin: 12% (in line with 2Q 2023). Over the last 3 years on average, earnings per share has increased by 35% per year whereas the company’s share price has increased by 38% per year.
お知らせ • Jul 25MedCap AB (publ) to Report Q2, 2025 Results on Jul 23, 2025MedCap AB (publ) announced that they will report Q2, 2025 results on Jul 23, 2025
Buy Or Sell Opportunity • Jul 01Now 17% undervaluedOver the last 90 days, the stock has risen 40% to kr523. The fair value is estimated to be kr631, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 34%.
Buy Or Sell Opportunity • Jun 25Now 21% undervaluedOver the last 90 days, the stock has risen 32% to kr500. The fair value is estimated to be kr629, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 34%.
分析記事 • Jun 06Estimating The Intrinsic Value Of MedCap AB (publ) (STO:MCAP)Key Insights The projected fair value for MedCap is kr631 based on 2 Stage Free Cash Flow to Equity Current share price...
分析記事 • May 21MedCap AB (publ) (STO:MCAP) Stocks Shoot Up 33% But Its P/E Still Looks ReasonableThe MedCap AB (publ) ( STO:MCAP ) share price has done very well over the last month, posting an excellent gain of 33...
Buy Or Sell Opportunity • May 13Now 21% undervaluedOver the last 90 days, the stock has risen 26% to kr494. The fair value is estimated to be kr626, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 34%.
お知らせ • May 12MedCap AB (publ) to Report Q1, 2025 Results on Apr 29, 2025MedCap AB (publ) announced that they will report Q1, 2025 results on Apr 29, 2025
分析記事 • May 04Should You Be Adding MedCap (STO:MCAP) To Your Watchlist Today?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Reported Earnings • May 04First quarter 2024 earnings released: EPS: kr3.78 (vs kr1.68 in 1Q 2023)First quarter 2024 results: EPS: kr3.78 (up from kr1.68 in 1Q 2023). Revenue: kr463.1m (up 22% from 1Q 2023). Net income: kr56.0m (up 126% from 1Q 2023). Profit margin: 12% (up from 6.5% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth.
お知らせ • Apr 03MedCap AB (publ), Annual General Meeting, May 06, 2024MedCap AB (publ), Annual General Meeting, May 06, 2024.
お知らせ • Mar 29MedCap AB (publ) to Report Fiscal Year 2024 Results on Jan 31, 2025MedCap AB (publ) announced that they will report fiscal year 2024 results on Jan 31, 2025
分析記事 • Feb 15MedCap AB (publ)'s (STO:MCAP) P/E Is Still On The Mark Following 25% Share Price BounceDespite an already strong run, MedCap AB (publ) ( STO:MCAP ) shares have been powering on, with a gain of 25% in the...
Reported Earnings • Feb 02Full year 2023 earnings released: EPS: kr11.63 (vs kr7.94 in FY 2022)Full year 2023 results: EPS: kr11.63 (up from kr7.94 in FY 2022). Revenue: kr1.60b (up 43% from FY 2022). Net income: kr172.2m (up 46% from FY 2022). Profit margin: 11% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Feb 01Investor sentiment improves as stock rises 19%After last week's 19% share price gain to kr380, the stock trades at a trailing P/E ratio of 37.4x. Average trailing P/E is 49x in the Life Sciences industry in Sweden. Total returns to shareholders of 88% over the past three years.
分析記事 • Dec 21Is Now The Time To Put MedCap (STO:MCAP) On Your Watchlist?The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
お知らせ • Oct 29MedCap AB (publ) to Report Q3, 2024 Results on Oct 25, 2024MedCap AB (publ) announced that they will report Q3, 2024 results on Oct 25, 2024
Reported Earnings • Oct 29Third quarter 2023 earnings released: EPS: kr2.59 (vs kr2.47 in 3Q 2022)Third quarter 2023 results: EPS: kr2.59 (up from kr2.47 in 3Q 2022). Revenue: kr368.2m (up 52% from 3Q 2022). Net income: kr38.3m (up 4.6% from 3Q 2022). Profit margin: 10% (down from 15% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 31MedCap AB (publ) to Report First Half, 2024 Results on Jul 19, 2024MedCap AB (publ) announced that they will report first half, 2024 results on Jul 19, 2024
Reported Earnings • Jul 29Second quarter 2023 earnings released: EPS: kr3.16 (vs kr1.42 in 2Q 2022)Second quarter 2023 results: EPS: kr3.16 (up from kr1.42 in 2Q 2022). Revenue: kr390.0m (up 37% from 2Q 2022). Net income: kr46.8m (up 123% from 2Q 2022). Profit margin: 12% (up from 7.4% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 32% per year whereas the company’s share price has increased by 27% per year.
お知らせ • Jul 25MedCap AB (publ) (OM:MCAP) signed an agreement to acquire SurgiCube International B.V. for €8 million.MedCap AB (publ) (OM:MCAP) signed an agreement to acquire Surgicube International B.V. for €8 million on July 24, 2023. Under the transaction, MedCap pays €6 million and adjustments for net debt / cash at closing and an earn-out up to €2 million based on the gross profit growth until December 2024. SurgiCube’s sales in the last 12 months amounted to approximately €3.7 million with almost 24% EBITDA-margin. Key individuals in the business have committed to remain as minority owners, and the former majority owner Ger Vijfvinkel has committed to remain as managing director and then as advisor during a transition phase.
分析記事 • May 06Do MedCap's (STO:MCAP) Earnings Warrant Your Attention?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
お知らせ • May 05MedCap AB (publ) to Report Q1, 2024 Results on May 03, 2024MedCap AB (publ) announced that they will report Q1, 2024 results on May 03, 2024
Reported Earnings • May 03First quarter 2023 earnings released: EPS: kr1.68 (vs kr1.32 in 1Q 2022)First quarter 2023 results: EPS: kr1.68 (up from kr1.32 in 1Q 2022). Revenue: kr384.0m (up 46% from 1Q 2022). Net income: kr24.8m (up 27% from 1Q 2022). Profit margin: 6.5% (down from 7.5% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Feb 12Full year 2022 earnings released: EPS: kr7.94 (vs kr6.52 in FY 2021)Full year 2022 results: EPS: kr7.94 (up from kr6.52 in FY 2021). Revenue: kr1.15b (up 24% from FY 2021). Net income: kr117.6m (up 22% from FY 2021). Profit margin: 10% (in line with FY 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
分析記事 • Nov 23These 4 Measures Indicate That MedCap (STO:MCAP) Is Using Debt SafelyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Board Change • Nov 16High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. 1 highly experienced director. Independent Director Anders Hansen is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 30Third quarter 2022 earnings released: EPS: kr2.47 (vs kr1.73 in 3Q 2021)Third quarter 2022 results: EPS: kr2.47 (up from kr1.73 in 3Q 2021). Revenue: kr264.0m (up 31% from 3Q 2021). Net income: kr36.6m (up 43% from 3Q 2021). Profit margin: 14% (up from 13% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.
分析記事 • Sep 21We Ran A Stock Scan For Earnings Growth And MedCap (STO:MCAP) Passed With EaseFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Buying Opportunity • Sep 13Now 21% undervaluedOver the last 90 days, the stock is up 17%. The fair value is estimated to be kr267, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 28%.
Buying Opportunity • Aug 02Now 21% undervaluedOver the last 90 days, the stock is up 36%. The fair value is estimated to be kr273, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 28%.
お知らせ • Jul 31MedCap AB (publ) to Report Q2, 2023 Results on Jul 28, 2023MedCap AB (publ) announced that they will report Q2, 2023 results on Jul 28, 2023
Board Change • Jul 30High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. 1 highly experienced director. Independent Director Anders Hansen is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jun 02High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. 1 highly experienced director. Independent Director Anders Hansen is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 12+ 1 more updateMedCap AB (publ) to Report Q1, 2023 Results on May 03, 2023MedCap AB (publ) announced that they will report Q1, 2023 results on May 03, 2023
Reported Earnings • May 06First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2022 results: EPS: kr1.32 (up from kr0.99 in 1Q 2021). Revenue: kr265.8m (up 19% from 1Q 2021). Net income: kr19.6m (up 34% from 1Q 2021). Profit margin: 7.4% (up from 6.6% in 1Q 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 4.3%. Earnings per share (EPS) exceeded analyst estimates by 13%. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
分析記事 • Apr 29Does MedCap (STO:MCAP) Deserve A Spot On Your Watchlist?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
お知らせ • Mar 29MedCap AB (publ) to Report Q4, 2022 Results on Feb 10, 2023MedCap AB (publ) announced that they will report Q4, 2022 results on Feb 10, 2023
Reported Earnings • Feb 11Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: EPS: kr6.52 (up from kr4.36 in FY 2020). Revenue: kr939.6m (up 15% from FY 2020). Net income: kr96.5m (up 54% from FY 2020). Profit margin: 10% (up from 7.6% in FY 2020). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 4.3%. Earnings per share (EPS) exceeded analyst estimates by 13%. Over the last 3 years on average, earnings per share has increased by 29% per year and the company’s share price has also increased by 29% per year.
分析記事 • Feb 01MedCap (STO:MCAP) Seems To Use Debt Rather SparinglyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Valuation Update With 7 Day Price Move • Jan 31Investor sentiment improved over the past weekAfter last week's 18% share price gain to kr162, the stock trades at a trailing P/E ratio of 31.3x. Average trailing P/E is 51x in the Life Sciences industry in Sweden. Total returns to shareholders of 94% over the past three years.
Buying Opportunity • Jan 21Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 24%. The fair value is estimated to be kr184, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.4% per annum over the last 3 years. Earnings per share has grown by 32% per annum over the last 3 years.
Board Change • Jan 02High number of new directorsChairman Karl Tobieson was the last director to join the board, commencing their role in 2021.
Recent Insider Transactions • Dec 30Chief Executive Officer recently bought kr348k worth of stockOn the 27th of December, Anders Dahlberg bought around 2k shares on-market at roughly kr174 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr828k. Anders has been a buyer over the last 12 months, purchasing a net total of kr1.1m worth in shares.
Recent Insider Transactions • Dec 15Investment Manager recently bought kr828k worth of stockOn the 13th of December, Lars Ångman bought around 5k shares on-market at roughly kr166 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr1.9m more in shares than they have sold in the last 12 months.
Reported Earnings • Oct 30Third quarter 2021 earnings released: EPS kr1.73 (vs kr0.89 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr216.0m (up 23% from 3Q 2020). Net income: kr25.6m (up 95% from 3Q 2020). Profit margin: 12% (up from 7.5% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 32% per year whereas the company’s share price has increased by 34% per year.
分析記事 • Aug 03Should You Be Adding MedCap (STO:MCAP) To Your Watchlist Today?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
Reported Earnings • Jul 31Second quarter 2021 earnings released: EPS kr1.06 (vs kr1.33 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: kr237.1m (up 13% from 2Q 2020). Net income: kr15.7m (down 18% from 2Q 2020). Profit margin: 6.6% (down from 9.1% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.
分析記事 • May 27Does MedCap (STO:MCAP) Have A Healthy Balance Sheet?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Valuation Update With 7 Day Price Move • May 12Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to kr206, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 40x in the Life Sciences industry in Europe. Total returns to shareholders of 170% over the past three years.
Recent Insider Transactions • May 09Independent Chairman of the Board recently bought kr1.1m worth of stockOn the 7th of May, Peter von Ehrenheim bought around 5k shares on-market at roughly kr220 per share. This was the largest purchase by an insider in the last 3 months. This was Peter's only on-market trade for the last 12 months.